Zydus Lifesciences Settles US Generic Pricing Antitrust Litigation for USD 5.9 Million
Zydus Lifesciences Ltd 路 Others (Uncategorized) 路 05 Sept 2026, 10:43 pm
Zydus Lifesciences Settles US Generic Pricing Antitrust Litigation for USD 5.9 Million Zydus Lifesciences announced on 5th Sep'26 that its wholly owned US subsidiary, Zydus Pharmaceuticals USA Inc. (ZPUI), entered into a settlement agreement with a putative class of Indirect Reseller Plaintiffs. The agreement resolves litigation under MDL No. 2724 (*In re Generic Pharmaceuticals Pricing Antitrust Litigation*) pending in the US District Court for the Eastern District of Pennsylvania. Under the terms, ZPUI will pay USD 5.9mn for a full and final release of all claims, executed without any admission of fault or wrongdoing.
Original exchange filing (PDF)
More announcements from Zydus Lifesciences Ltd
- Press Release 路 14 Nov 2026
- Completion of transaction 路 12 Nov 2026
- Transcript of the post results earnings call held on November 4, 2026. 路 07 Nov 2026
- Press Release 路 07 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of India 路 06 Nov 2026
- Investor Conference 路 06 Nov 2026
- Audio recording of the Company's Investor Call 路 05 Nov 2026
- Press Release 路 04 Nov 2026
